The cluster shows institutional de-risking by sovereign and quant funds, with no active manager conviction on the buy side. Given the 45-day reporting lag, these positions may have been further adjusted. Monitor for additional insider selling or clinical trial updates that could explain the selling pattern. The stock's high short interest and low liquidity amplify downside risk.
Executive Summary
A mixed institutional cluster in Kyverna Therapeutics (KYTX) for Q3 2024 shows two small buyers (Schwab and Federated Hermes) adding modest positions totaling $971K, while three larger sellers—Norges Bank, Citadel, and Legal & General—reduced holdings by $2.2M, including near-exits by Norges and Legal & General. The net selling pressure of ~$2.2M against minimal buying suggests institutional de-risking, consistent with the stock's post-IPO volatility and lack of near-term revenue catalysts.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$1.3M
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Schwab | ADD | +33.2% | $815.0K | -$123.2K |
| Federated Hermes | DOUBLED | +100% | $156.0K | $36.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Norges Bank | NEAR_EXIT | -77.9% | $1.4M | -$1.2M |
| Citadel | TRIM | -39.6% | $1.7M | -$1.0M |
| Legal & General Group | NEAR_EXIT | -76.9% | $55.0K | -$47.1K |
Key Facts
- Aggregate net selling of ~$2.2M by 3 institutions vs. $971K buying by 2 institutions
- Norges Bank (sovereign) cut 77.9% of its position, exiting ~$1.16M in value
- Citadel (quant) trimmed 39.6% of its stake, selling ~$1.04M in value
- Federated Hermes doubled its small position (+$36K), but total buying is negligible relative to selling
- Schwab (mega-passive) added 33.2% shares, likely index rebalancing, not active conviction
Financial Impact
3 institutions sold ~$2.24M in KYTX shares while 2 institutions bought ~$971K, resulting in net institutional outflow of ~$1.27M
Risk Factors
- Continued institutional selling pressure if the Q4 2024 13F shows further reductions
- No near-term revenue catalyst for this pre-commercial biotech
- Low trading volume could exacerbate price moves on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-KYTX-2024-Q3 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | — |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | — |
Aug 11, 2026 11w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | — |
Aug 11, 2026 11w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | — |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | — |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | — |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | — |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | — |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | — |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers